Literature DB >> 26169400

Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.

Sam Ogwang1, Caryn E Good2, Brenda Okware3, Mary Nsereko3, Michael R Jacobs2, W Henry Boom4, Charles M Bark5.   

Abstract

Additional drugs are needed for the treatment of multidrug-resistant tuberculosis (TB). Sulfamethoxazole has been shown to have in vitro activity against Mycobacterium tuberculosis; however, there is concern about resistance given the widespread use of trimethoprim-sulfamethoxazole prophylaxis among HIV-infected patients in sub-Saharan Africa. Thirty-eight of 40 Mycobacterium tuberculosis isolates (95%) from pretreatment sputum samples from Ugandan adults with pulmonary TB, including HIV-infected patients taking trimethoprim-sulfamethoxazole prophylaxis, were susceptible with MICs of ≤38.4 μg/ml.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26169400      PMCID： PMC4538550          DOI： 10.1128/AAC.01101-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Progress in treatment of tuberculosis. Results of antimicrobial therapy in a group of 420 children with tuberculosis.

Authors:  E M LINCOLN; P G VERA CRUZ
Journal:  Pediatrics       Date:  1960-06       Impact factor: 7.124

2.  Tuberculous meningitis treatment with streptomycin, para-aminosalicylic acid and promizole, isoniazid and streptomycin, and isoniazid.

Authors:  H W SPIES; M H LEPPER; N H BLATT; H F DOWLING
Journal:  Am Rev Tuberc       Date:  1954-02

3.  Promizole treatment of miliary tuberculosis; toxic effects on thyroid gland and maturation.

Authors:  L MILGRAM; I LEVITT; M S UNNA
Journal:  Am Rev Tuberc       Date:  1947-02

4.  Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis.

Authors:  N Alsaad; T van der Laan; R van Altena; K R Wilting; T S van der Werf; Y Stienstra; D van Soolingen; J W C Alffenaar
Journal:  Int J Antimicrob Agents       Date:  2013-08-23       Impact factor: 5.283

5.  Tuberculosis and trimethoprim-sulfamethoxazole.

Authors:  Pierre Forgacs; Nancy L Wengenack; Leslie Hall; Sarah K Zimmerman; Mark L Silverman; Glenn D Roberts
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 6.  The early bactericidal activity of antituberculosis drugs.

Authors:  Andreas H Diacon; Peter R Donald
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01-06       Impact factor: 5.091

7.  Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan.

Authors:  Tsi-Shu Huang; Calvin M Kunin; Bo-Shiun Yan; Yao-Shen Chen; Susan Shin-Jung Lee; Wan Syu
Journal:  J Antimicrob Chemother       Date:  2011-11-29       Impact factor: 5.790

8.  Sulfamethoxazole enhances the antimycobacterial activity of rifampicin.

Authors:  Lubabalo Macingwana; Bienyameen Baker; Andile H Ngwane; Catriona Harper; Mark F Cotton; Anneke Hesseling; Andreas H Diacon; Paul van Helden; Ian Wiid
Journal:  J Antimicrob Chemother       Date:  2012-08-08       Impact factor: 5.790

9.  Tuberculosis in household contacts of infectious cases in Kampala, Uganda.

Authors:  D Guwatudde; M Nakakeeto; E C Jones-Lopez; A Maganda; A Chiunda; R D Mugerwa; J J Ellner; G Bukenya; C C Whalen
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

10.  The household contact study design for genetic epidemiological studies of infectious diseases.

Authors:  Catherine M Stein; Noémi B Hall; Lashaunda L Malone; Ezekiel Mupere
Journal:  Front Genet       Date:  2013-04-30       Impact factor: 4.599
View more
  3 in total

1.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

2.  The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates.

Authors:  Marissa B Guzzo; Qing Li; Hoang V Nguyen; W Henry Boom; Liem Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV.

Authors:  Stephane Wen-Wei Ku; Awachana Jiamsakul; Kedar Joshi; Mark Kristoffer Ungos Pasayan; Alvina Widhani; Romanee Chaiwarith; Sasisopin Kiertiburanakul; Anchalee Avihingsanon; Penh Sun Ly; Nagalingeswaran Kumarasamy; Cuong D Do; Tuti P Merati; Kinh Van Nguyen; Adeeba Kamarulzaman; Fujie Zhang; Man Po Lee; Jun Yong Choi; Junko Tanuma; Suwimon Khusuwan; Benedict Lim Heng Sim; Oon Tek Ng; Winai Ratanasuwan; Jeremy Ross; Wing-Wai Wong
Journal:  J Int AIDS Soc       Date:  2019-03       Impact factor: 5.396
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.